Physician profile
Parker E Bohm
NPI 1598299935
$457.90
in general payments reported to CMS, 2019-2025
16 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Neuro-Ophthalmology provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $46.81 · 2023: $182 · 2024: $112 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $64.88 | 2023 | Tepezza |
| Lundbeck LLC | $57.67 | 2022-2024 | Vyepti |
| Globus Medical, INC. | $54.69 | 2025 | Senza |
| Eisai INC. | $49.95 | 2023 | |
| Merz Pharmaceuticals, LLC | $33.63 | 2025 | Xeomin |
| Janssen Biotech, INC. | $29.35 | 2025 | |
| Celgene Corporation | $21.40 | 2022 | |
| Genentech USA, INC. | $19.54 | 2024 | Ocrevus, Ocrevus Zunovo |
| Banner Life Sciences, LLC | $19.48 | 2023 | |
| Kyowa Kirin, INC. | $18.55 | 2023 | Nourianz |
| Siemens Medical Solutions USA, INC. | $16.17 | 2023 | Magnetom Altea |
| Tg Therapeutics, INC. | $16.09 | 2024 | |
| Medtronic, INC. | $15.88 | 2024 | Synchromedii |
| Amylyx Pharmaceuticals, INC. | $14.13 | 2024 | Relyvrio |
| Biogen, INC. | $13.77 | 2024 | Skyclarys |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $12.72 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parker Bohm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.